If you would like to learn more about our technology, and the Extreme Diversity™ library and selection platform, please contact us at


Merck Collaboration and License Agreement

We have successfully identified and delivered orally-available cyclic peptides for a non-complement cardiovascular target with a large market opportunity, in connection with our April 2013 collaboration and license agreement with Merck.